1. °³¿ä
2. µ¿ÀǾî
3. Á¤ÀÇ
malignant histiocytosis ´Â ÁøÂ¥ Á¶Á÷±¸(true histiocytes) (monocyte macrophage) ÀÇ Àü½ÅÀûÀÎ Áõ½Ä (systemic proliferation) ÀÔ´Ï´Ù. Æó ¼Ò°ß (pulmonary manifestations) Àº µå¿îÀÏÀÔ´Ï´Ù. ±×·¯³ª ¶§¶§·Î ¹ß»ýÇÏ¸ç µå¹°°Ô´Â ÁúȯÀÇ °úÁ¤Áß¿¡ ¿ì¼¼ÇÏ°Ô ³ªÅ¸³ª±âµµ ÇÕ´Ï´Ù. 4. Áõ»ó
5. ¿øÀÎ,º´Å »ý¸®
6. Áø´Ü
malignant histiocytosis ÀÇ º´¸®´Â ÀÓÆÄÀý°ú °£, ºñÀå, bone marrow ÀÇ sinusoids ¿¡ ÀÖ´Â ¼¼Æ÷ÇÐÀûÀ¸·Î ¾Ç¼ºÀÎ (cytologically neoplastic) monocyte macrophages ÀÇ ºÐȰ¡ Ư¡ÀÔ´Ï´Ù. Áß¿äÇÑ Á¶Á÷ÇÐÀû ¼Ò°ß (histologic feature) À¸·Î´Â ¾Ç¼º ¼¼Æ÷ (neoplastic cells) ¿¡ ÀÇÇÑ erythrophagocytosis °¡ ¿ì¼¼ÇÏ°Ô ³ªÅ¸³³´Ï´Ù. monocyte-macrophage markers (lysozyme, alpha 1-antitrypsin, nonspecific esterase, monocytic antigens) ¸¦ À§ÇÑ immunocytochemistry ´Â Áø´Ü¿¡ µµ¿òÀ» ÁÙ ¼ö ÀÖ´Ù. Æó¿¡¼ malignant histiocytosis ÀÇ infiltrates ´Â Ư¡ÀûÀ¸·Î À§Ä¡°¡ Àӯļº (lymphangitic) ÀÌ¸ç °£Áú¼º (interstitial) ÀÔ´Ï´Ù.
ÆóħÀ± (pulmonary infiltrates) Àº ºó¹øÈ÷ interstitial edema, fibrosis, ±×¸®°í inflammatory cells µîÀÇ Æò°¡ÇÒ ¼ö ÀÖ´Â(appreciable) ¼Ò°ß (components) °ú µ¿¹ÝµË´Ï´Ù. malignant histiocytosis ´Â greater degree of cytologic atypia, absence of Langerhans cells ±×¸®°í presence of erythrophagocytosis ¿¡ ÀÇÇØ histiocytosis X ¿Í ±¸ºÐµË´Ï´Ù. Áø´ÜÇϱ⠾î·Á¿î °æ¿ì¿¡´Â ´Ù¾çÇÑ immunocytologic techniques ¿¡ ÀÇÇØ °¨º°Áø´Ü¿¡ µµ¿òÀ» ¹ÞÀ» ¼ö ÀÖ½À´Ï´Ù. 7. °æ°ú,¿¹ÈÄ
8. ÇÕº´Áõ
9. Ä¡·á
malignant histiocytosis ´Â aggressive ÇÑ multi-agent chemotherapy ·Î Ä¡·áÇÕ´Ï´Ù. ºñ·Ï ¶§¶§·Î Àå±â°£ »ýÁ¸ÇÏ´Â °æ¿ì°¡ ÀÖÀ¸³ª ÀϹÝÀûÀ¸·Î ¿¹Èİ¡ ºÒ·®ÇÕ´Ï´Ù. 10. ¿¹¹æ¹ý
11. ÀÌ·²¶© Àǻ翡°Ô
12. Á¦¸ñ¾øÀ½
malignant histiocytosis ´Â ´ëºÎºÐ ¹ß¿, °£ºñÁ¾´ë (hepatosplenomegaly), ºóÇ÷, ±×¸®°í Ç÷¼ÒÆÇ °¨¼ÒÁõ (thrombocytopenia) µîÀÇ ±Þ¼º ÁúȯÀ¸·Î ³ªÅ¸³³´Ï´Ù. Æó ħ¹üÀº ¼Ò¼öÀÇ È¯ÀÚ¿¡¼ ¹ß»ýÇÏ¸ç ±âħ, È£Èí°ï¶õ µîÀÇ Áõ»óÀÌ ³ªÅ¸³³´Ï´Ù. Æóħ¹üÀÌ Àִ ȯÀÚ¿¡¼ ÈäºÎ X-¼± »çÁø»ó bilateral reticulonodular infiltrates ÀÇ ¼Ò°ßÀ» ³ªÅ¸³À´Ï´Ù. 13.
|